An open-label single-center investigator-initiated exploratory clinical study in patients with refractory or recurrent solid tumors using SBRT as “in situ vaccination”: R-ISV-FOLactis trial. This is ...
Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, and Gencurix, Inc., a leading Korean developer of oncology testing solutions, today announced ...
Cancer diagnostics company GENCURIX said on the 2nd that it signed a strategic exclusive distribution agreement with Bio-Rad Laboratories, headquartered in California, to supply the digital PCR-based ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), and Gencurix, Inc. (KOSDAQ: 229000), announced the signing of a strategic agreement establishing Bio-Rad as the exclusive distributor of Gencurix’ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results